Literature DB >> 8813990

Antiretroviral drugs for AIDS.

J J Lipsky1.   

Abstract

Treatment of HIV disease with antiretroviral agents has changed considerably. We now know that monotherapy is not the best strategy in most cases to combat rapid turnover of virus and development of resistance (the exception being mother-to-child transmission) and various combination drug regimens are being explored. Apart from the main drug groups, consisting of nucleoside analogues, proteinase inhibitors, and reverse-transcriptase inhibitors, many new compounds are under development. The timing of therapy may likewise be important, and the indications of benefit from early initiation of treatment need to be confirmed in randomised trials. Overall, there is far more optimism about the use of drugs in HIV infection than there was several years ago.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813990     DOI: 10.1016/S0140-6736(95)12333-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Anti-HIV-1 efficacy of extracts from medicinal plants.

Authors:  Su-A Lee; Seong-Karp Hong; Chang-Il Suh; Mi-Hwa Oh; Jeong-Ho Park; Byoung-Wook Choi; Seung-Won Park; Soon-Young Paik
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

3.  Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV.

Authors:  Robert O Koch; Ivo W Graziadei; Robert Zangerle; Nikolaus Romani; Hans Maier; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2003-02-28       Impact factor: 1.704

4.  Hyperlipidemia under treatment with proteinase inhibitors.

Authors:  S Segerer; J R Bogner; R Walli; O Loch; F D Goebel
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

5.  Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.

Authors:  P A Napoli; M Dorrucci; D Serraino; P Pezzotti; S Franceschi; S Vella; G Rezza
Journal:  Eur J Epidemiol       Date:  1998-01       Impact factor: 8.082

Review 6.  Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Authors:  M Barry; F Mulcahy; C Merry; S Gibbons; D Back
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

Review 7.  Potential anti-HIV agents from marine resources: an overview.

Authors:  Thanh-Sang Vo; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-11-29       Impact factor: 5.118

Review 8.  Liver as a target of human immunodeficiency virus infection.

Authors:  Murali Ganesan; Larisa Y Poluektova; Kusum K Kharbanda; Natalia A Osna
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

Review 9.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

10.  Evaluation of quantitative liver function tests in HIV-positive patients under anti-retroviral therapy.

Authors:  M Miller; A Kahraman; B Ross; M Beste; Guido Gerken
Journal:  Eur J Med Res       Date:  2009-09-01       Impact factor: 2.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.